English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, June 7, 2022
华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性
華領醫藥在2022ADA科學年會公佈多格列艾汀能夠明顯改善2型糖尿病患者和GCK-MODY患者的胰島素早相分泌和葡萄糖敏感性
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022
Friday, May 13, 2022
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文
祝賀!國際頂級醫學期刊《自然-醫學》同時發表兩篇關於華領醫藥全球首創糖尿病新藥多格列艾汀的III期研究結果的同行評議論文
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine
Thursday, March 17, 2022
华领医药公布2021年全年业绩
華領醫藥公佈2021年全年業績
Hua Medicine Announces 2021 Annual Results
Sunday, September 26, 2021
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575